About CureVac: Collaborations
United by purpose, strengthened by collective action
We’re not alone in our drive to see messenger RNA (mRNA) therapeutics revolutionize health care. And we will always do whatever it takes to accelerate progress. That’s why we collaborate with pharmaceutical companies, biotechnology innovators, and nonprofit organizations that share our vision, amplify the impact of our technology, and bring life-changing treatments to more people around the world, faster.
Current strategic collaborations
The University of Texas MD Anderson Cancer Center
This collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson’s expertise in cancer antigen discovery and validation, translational drug development, and clinical research. The collaboration focuses on the development of differentiated cancer immunotherapy candidates in select hematologic and solid tumor indications with high unmet medical need.
Bill & Melinda Gates Foundation
The common goal of the partnership between CureVac and the Bill & Melinda Gates Foundation is to develop mRNA-based vaccines for various infectious diseases that have an enormous impact on global health.
CRISPR Therapeutics
CureVac is collaborating with CRISPR Therapeutics, a genome editing company focused on creating transformative gene-based medicines for serious diseases, to develop CRISPR-based therapeutics in select disease areas. Under the terms of the agreement, CureVac develops novel Cas9 mRNA constructs with improved properties for gene editing applications, such as increased potency, decreased duration of expression, and reduced potential for immunogenicity.
myNEO Therapeutics
CureVac is partnering with myNEO Therapeutics to identify novel antigen targets for mRNA-based cancer immunotherapy development. To achieve this goal, myNEO Therapeutics leverages its biological datasets, integrated machine learning, and bioinformatics platform to identify and validate specific antigen targets predicted to elicit a strong immune response.
Current technology collaborations
Acuitas Therapeutics Ltd
CureVac is working with with Acuitas Therapeutics Ltd, a company that specializes in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. This collaboration will allow CureVac to access the patent portfolio and know-how of Acuitas and its lipid technology. The objective of the collaboration is to develop LNP-formulated mRNA product candidates.
Arcturus Therapeutics Ltd
CureVac is collaborating with Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, to access Arcturus’ lipid-mediated delivery intellectual property to develop mRNA product candidates.
Tesla Automation
CureVac is partnering with Tesla Automation to make portable molecular RNA printers, with the goal of producing therapeutics at scale globally by eschewing traditional logistical concerns.
Partner with us
We are always looking for new strategic partnerships that can help take our mRNA technology to the next level and into the hands of those who need it most.
Explore how our team and collaborators are forging a new frontier of mRNA medicines.